这款国产 PD-1 在海外又有新消息

Insight数据库
Jul 11, 2025

7 月 10 日,百济神州宣布欧盟委员会(EC)已批准百泽安®(替雷利珠单抗)联合吉西他滨和顺铂用于不适合根治性手术或放疗的转移或复发性鼻咽癌(NPC)成年患者的一线治疗。截图来源:企业官微此次鼻咽癌适应症获批是基于RATIONALE-309(NCT03924986)研究的结果。该研究是一项双盲、安慰剂对照、多中心 III 期研究,263 例患者被随机分配接受替雷利珠单抗联合吉西他滨和顺铂或安慰剂...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10